Simulation driven identification of combinations for the WEE1 inhibitor Debio 0123 results in synergistic effect with cabozantinib validated in vivo

Debio 0123 is a novel, orally-available, selective ATP-competitive WEE1 inhibitor with potential as a best-in-class, brain-penetrant treatment being evaluated in Phase I trials for solid tumors. WEE1, a tyrosine kinase activated by DNA damage, acts at the S-phase and G2/M checkpoints to facilitate DNA repair before mitosis.